Proliferative retinopathies, driven by abnormal retinal blood vessel growth, are a leading cause of irreversible vision loss. These conditions, including diabetic retinopathy and age-related macular degeneration (AMD), threaten millions globally.

Proliferative retinopathies, driven by abnormal retinal blood vessel growth, are a leading cause of irreversible vision loss. These conditions, including diabetic retinopathy and age-related macular degeneration (AMD), threaten millions globally.

Frontline treatments like anti-VEGF agents (e.g., aflibercept) and corticosteroids target disease mechanisms with molecular precision. These rigorously validated therapies halt active progression but are rarely used preventively.

Dietary supplements, such as the AREDS2 formula (vitamins C/E, zinc, lutein) and omega-3 fatty acids, combat oxidative stress and inflammation. Emerging evidence suggests they reduce baseline risk and amplify treatment efficacy, offering long-term retinal protection.

Pharmaceuticals act as urgent responders, while supplements build resilience. Studies highlight their combined potential to slow progression in AMD and diabetic retinopathy—but caution is key.

Supplements lack the stringent oversight of drugs, and interactions (e.g., altered drug absorption) pose risks. Clinician guidance is critical to balance benefits and safety.

High-risk patients may benefit from preventive nutraceuticals, while those on pharmacotherapy could see enhanced outcomes with adjunctive antioxidants. Collaboration between patients and providers ensures optimized, individualized strategies.

Source: https://encyclopedia.pub/image/3247

As research evolves, merging pharmacotherapy and supplements promises to redefine standards of care—proactively preserving vision in an aging population through immediate action and sustained protection.

For more details about neovascular eye diseases, you can view the online video entitled "Pharmacotherapy and Nutraceuticals for Neovascular Eye Diseases".